Versant Venture Capital VI, L.P.
CIK 1687880 · last filed 2025-08-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LENZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ | 10%+ Owner | 2,299,292 | $3.15 | $7.23M | -$216.73M | 3 | 2025-08-26 |
| IPSC | 10%+ Owner | 13,259,905 | $1.42 | $18.83M | $0 | 1 | 2021-12-28 |
| LENZ Therapeutics, Inc. (GRPH) Delisted | 10%+ Owner | 2,319,446 | $22.26 | $51.63M | $18.36M | 1 | 2021-07-01 |
| BDTX | 10%+ Owner | 4,343,210 | $1.69 | $7.34M | $39.27M | 9 | 2020-11-25 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 3,754,051 | $60.05 | $225.43M | $0 | 1 | 2020-07-21 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 7,297,318 | $54.65 | $398.80M | -$24.20M | 8 | 2020-07-10 |
| Oyster Point Pharma, Inc. (OYST) Delisted | 10%+ Owner | 2,945,158 | $11.17 | $32.90M | $84.96M | 1 | 2019-11-04 |
Recent Filings · Page 2 of 3
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-13 | BDTX | Mixed | −3,862,392 | -$2.13M | EDGAR |
| 2020-10-28 | BDTX | Sell (S) | −35,612 | -$1.19M | EDGAR |
| 2020-10-20 | BDTX | Sell (S) | −62,984 | -$2.11M | EDGAR |
| 2020-10-08 | BDTX | Mixed | −1,342,136 | -$6.14M | EDGAR |
| 2020-09-21 | BDTX | Other (J) | −2,916,864 | $0 | EDGAR |
| 2020-08-20 | BDTX | Other (J) | −1,200,000 | $0 | EDGAR |
| 2020-07-21 | Pandion Therapeutics, Inc. (PAND) Delisted | Conv (C) | +22,524,306 | $0 | EDGAR |
| 2020-07-10 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −159,171 | -$3.18M | EDGAR |
| 2020-07-10 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | −2,269,761 | -$4.28M | EDGAR |
| 2020-02-05 | BDTX | Mixed | +42,211,572 | $68.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.